vs
Side-by-side financial comparison of CRYO CELL INTERNATIONAL INC (CCEL) and Fresenius Medical Care AG (FMS). Click either name above to swap in a different company.
Fresenius Medical Care AG is the larger business by last-quarter revenue ($5.5B vs $7.8M, roughly 698.1× CRYO CELL INTERNATIONAL INC). Fresenius Medical Care AG runs the higher net margin — 7.9% vs -48.7%, a 56.6% gap on every dollar of revenue. On growth, Fresenius Medical Care AG posted the faster year-over-year revenue change (-0.3% vs -2.3%).
Cryo-Cell International, Inc. is a cord blood bank. It was founded by Dan Richard in 1989. Cryo-Cell International is the first private cord blood bank to separate and store stem cells. Cryo-Cell is headquartered outside of Tampa, in Oldsmar, Florida. In January 1997, the Company's stock began trading on the NASDAQ Small Cap market under symbol CCEL.
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives.
CCEL vs FMS — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $7.8M | $5.5B |
| Net Profit | $-3.8M | $434.2M |
| Gross Margin | 77.9% | 27.4% |
| Operating Margin | -50.6% | 11.7% |
| Net Margin | -48.7% | 7.9% |
| Revenue YoY | -2.3% | -0.3% |
| Net Profit YoY | -105.1% | 240.4% |
| EPS (diluted) | $-0.46 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.8M | $5.5B | ||
| Q3 25 | $7.8M | — | ||
| Q2 25 | $7.9M | — | ||
| Q1 25 | $8.0M | — | ||
| Q4 24 | $8.0M | $5.5B | ||
| Q3 24 | $8.1M | — | ||
| Q2 24 | $8.0M | — | ||
| Q1 24 | $7.9M | — |
| Q4 25 | $-3.8M | $434.2M | ||
| Q3 25 | $749.4K | — | ||
| Q2 25 | $355.8K | — | ||
| Q1 25 | $282.9K | — | ||
| Q4 24 | $-1.9M | $127.6M | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $655.8K | — | ||
| Q1 24 | $556.2K | — |
| Q4 25 | 77.9% | 27.4% | ||
| Q3 25 | 77.0% | — | ||
| Q2 25 | 76.6% | — | ||
| Q1 25 | 75.1% | — | ||
| Q4 24 | 78.4% | 25.0% | ||
| Q3 24 | 73.6% | — | ||
| Q2 24 | 74.8% | — | ||
| Q1 24 | 73.7% | — |
| Q4 25 | -50.6% | 11.7% | ||
| Q3 25 | 24.3% | — | ||
| Q2 25 | 18.8% | — | ||
| Q1 25 | 13.3% | — | ||
| Q4 24 | -1.5% | 5.1% | ||
| Q3 24 | 17.2% | — | ||
| Q2 24 | 17.3% | — | ||
| Q1 24 | 10.5% | — |
| Q4 25 | -48.7% | 7.9% | ||
| Q3 25 | 9.6% | — | ||
| Q2 25 | 4.5% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | -23.2% | 2.3% | ||
| Q3 24 | 13.0% | — | ||
| Q2 24 | 8.2% | — | ||
| Q1 24 | 7.1% | — |
| Q4 25 | $-0.46 | — | ||
| Q3 25 | $0.09 | — | ||
| Q2 25 | $0.04 | — | ||
| Q1 25 | $0.03 | — | ||
| Q4 24 | $-0.23 | — | ||
| Q3 24 | $0.13 | — | ||
| Q2 24 | $0.08 | — | ||
| Q1 24 | $0.07 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.3M | $1.7B |
| Total DebtLower is stronger | $8.4M | — |
| Stockholders' EquityBook value | $-18.6M | $15.4B |
| Total Assets | $61.7M | $33.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.3M | $1.7B | ||
| Q3 25 | $3.2M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $3.5M | — | ||
| Q4 24 | $3.5M | $1.3B | ||
| Q3 24 | $2.1M | — | ||
| Q2 24 | $1.5M | — | ||
| Q1 24 | $979.6K | — |
| Q4 25 | $8.4M | — | ||
| Q3 25 | $8.4M | — | ||
| Q2 25 | $8.4M | — | ||
| Q1 25 | $8.5M | — | ||
| Q4 24 | $8.5M | — | ||
| Q3 24 | $8.5M | — | ||
| Q2 24 | $8.5M | — | ||
| Q1 24 | $8.6M | — |
| Q4 25 | $-18.6M | $15.4B | ||
| Q3 25 | $-14.8M | — | ||
| Q2 25 | $-15.6M | — | ||
| Q1 25 | $-14.7M | — | ||
| Q4 24 | $-13.2M | $17.0B | ||
| Q3 24 | $-9.6M | — | ||
| Q2 24 | $-10.7M | — | ||
| Q1 24 | $-10.3M | — |
| Q4 25 | $61.7M | $33.5B | ||
| Q3 25 | $63.2M | — | ||
| Q2 25 | $64.4M | — | ||
| Q1 25 | $64.4M | — | ||
| Q4 24 | $64.7M | $36.3B | ||
| Q3 24 | $62.9M | — | ||
| Q2 24 | $62.6M | — | ||
| Q1 24 | $61.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.3M | $2.9B |
| Free Cash FlowOCF − Capex | $1.2M | — |
| FCF MarginFCF / Revenue | 15.5% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | — | 6.67× |
| TTM Free Cash FlowTrailing 4 quarters | $5.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3M | $2.9B | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $707.0K | — | ||
| Q1 25 | $954.1K | — | ||
| Q4 24 | $2.2M | $2.6B | ||
| Q3 24 | $2.4M | — | ||
| Q2 24 | $1.8M | — | ||
| Q1 24 | $-356.9K | — |
| Q4 25 | $1.2M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $644.6K | — | ||
| Q1 25 | $892.0K | — | ||
| Q4 24 | $2.1M | — | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | $21.5K | — | ||
| Q1 24 | $-814.6K | — |
| Q4 25 | 15.5% | — | ||
| Q3 25 | 31.9% | — | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 11.2% | — | ||
| Q4 24 | 26.8% | — | ||
| Q3 24 | 27.9% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | -10.4% | — |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 2.3% | — | ||
| Q2 24 | 21.8% | — | ||
| Q1 24 | 5.8% | — |
| Q4 25 | — | 6.67× | ||
| Q3 25 | 3.38× | — | ||
| Q2 25 | 1.99× | — | ||
| Q1 25 | 3.37× | — | ||
| Q4 24 | — | 20.20× | ||
| Q3 24 | 2.32× | — | ||
| Q2 24 | 2.70× | — | ||
| Q1 24 | -0.64× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
